-
PET是核医学领域较先进的分子影像学技术,可从分子水平动态观察受体、基因表达和细胞代谢等的变化情况。正电子放射性核素显像剂与PET技术结合可实时、定量地对病变相关生物靶点进行分析,将肿瘤生物学行为可视化。近年来,尽管11C、68Ga、64Cu、89Zr及124I标记的正电子分子探针在临床中的应用逐渐增多,但18F标记的分子探针具有较高的显像灵敏度及空间分辨率,故更适合用于PET肿瘤显像。
18F-AlF标记的多肽分子探针在PET肿瘤显像中的研究进展
Research progress of 18F-AlF-labeled peptide molecular probes in PET tumor imaging
-
摘要: 随着PET在临床中的广泛应用,18F-氟化铝(AlF)标记的多肽分子探针也备受关注。其标记方法简便易行,PET显像的灵敏度及空间分辨率高,可示踪多种生物靶点,从而为肿瘤的精准诊疗提供重要信息,且部分18F-AlF标记的多肽分子探针已进入临床研究阶段,具有良好的应用前景。笔者对18F-AlF标记的多肽生物靶向分子探针在PET肿瘤显像中的研究进展进行综述。
-
关键词:
- 分子探针 /
- 分子影像 /
- 氟脱氧葡萄糖F18 /
- 正电子发射断层显像术 /
- 生物靶点
Abstract: With the wide application of PET in clinic, 18F-AlF-labeled peptide biomolecular probes are increasing in the spotlight. The procedure of 18F-AlF labeling of biomolecule conjugates is simple, valid and has tremendous potential. 18F-AlF-biomolecule conjugates PET imaging has high sensitivity and spatial resolution, with ideal quantification properties to trace biological targets of various tumors, so as to provide important information for accurate diagnosis and treatment of tumors. Part of them are in clinical research stage and show a broad scope in future clinical application. In this paper, the authors review the current process of 18F-AlF-labeled peptide molecular probes for PET tumor imaging. -
[1] Richter S, Wuest F. 18F-labeled peptides: the future is bright[J/OL]. Molecules, 2014, 19(12): 20536−20556[2020-12-24]. https://www.mdpi.com/1420-3049/19/12/20536. DOI: 10.3390/ molecules191220536. [2] 张晓, 兰晓莉, 胡帆, 等. 点击化学在分子影像学中的应用和进展[J]. 国际放射医学核医学杂志, 2016, 40(3): 196−201. DOI: 10.3760/cma.j.issn.1673-4114.2016.03.008.
Zhang X, Lan XL, Hu F, et al. Applications and advances of click chemistry in molecular imaging[J]. Int J Radiat Med Nucl Med, 2016, 40(3): 196−201. DOI: 10.3760/cma.j.issn.1673-4114.2016.03.008.[3] Kumar K, Ghosh A. 18F-AlF labeled peptide and protein conjugates as positron emission tomography imaging pharmaceuticals[J]. Bioconjug Chem, 2018, 29(4): 953−975. DOI: 10.1021/acs.Bioconjchem.7b00817. [4] Cleeren F, Lecina J, Bridoux J, et al. Direct fluorine-18 labeling of heat-sensitive biomolecules for positron emission tomography imaging using the Al18F-RESCA method[J]. Nat Protoc, 2018, 13(10): 2330−2347. DOI: 10.1038/s41596-018-0040-7. [5] Liu SL, Liu HG, Jiang H, et al. One-step radiosynthesis of 18F-AlF-NOTA-RGD2 for tumor angiogenesis PET imaging[J]. Eur J Nucl Med Mol Imaging, 2011, 38(9): 1732−1741. DOI: 10.1007/s00259-011-1847-4. [6] Wan WX, Guo N, Pan DH, et al. First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination[J]. J Nucl Med, 2013, 54(5): 691−698. DOI: 10.2967/jnumed.112.113563. [7] Zhang H, Liu N, Gao S, et al. Can an 18F-ALF-NOTA-PRGD2 PET/CT scan predict treatment sensitivity to concurrent chemoradiotherapy in patients with newly diagnosed glioblastoma?[J]. J Nucl Med, 2016, 57(4): 524−529. DOI: 10.2967/jnumed.115.165514. [8] Li L, Ma L, Shang DP, et al. Pretreatment PET/CT imaging of angiogenesis based on 18F-RGD tracer uptake may predict antiangiogenic response[J]. Eur J Nucl Med Mol Imaging, 2019, 46(4): 940−947. DOI: 10.1007/s00259-018-4143-8. [9] Pan DH, Yan YJ, Yang RH, et al. PET imaging of prostate tumors with 18F-Al-NOTA-MATBBN[J]. Contrast Media Mol Imaging, 2014, 9(5): 342−348. DOI: 10.1002/cmmi.1583. [10] Carlucci G, Kuipers A, Ananias HJK, et al. GRPR-selective PET imaging of prostate cancer using [18F]-lanthionine-bombesin analogs[J]. Peptides, 2015, 67: 45−54. DOI: 10.1016/j.peptides.2015.03.004. [11] Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018[J]. Eur J Cancer, 2018, 103: 356−387. DOI: 10.1016/j.ejca.2018.07.005. [12] Boschi S, Lee JT, Beykan S, et al. Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand[J]. Eur J Nucl Med Mol Imaging, 2016, 43(12): 2122−2130. DOI: 10.1007/s00259-016-3437-y. [13] Liu TL, Liu C, Xu XX, et al. Preclinical evaluation and pilot clinical study of Al18F-PSMA-BCH for prostate cancer PET imaging[J]. J Nucl Med, 2019, 60(9): 1284−1292. DOI: 10.2967/jnumed.118.221671. [14] Hope TA, Bergsland EK, Bozkurt MF, et al. Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors[J]. J Nucl Med, 2018, 59(1): 66−74. DOI: 10.2967/jnumed.117.202275. [15] Long TT, Yang NG, Zhou M, et al. Clinical application of 18F-AlF-NOTA-octreotide PET/CT in combination with 18F-FDG PET/CT for imaging neuroendocrine neoplasms[J]. Clin Nucl Med, 2019, 44(6): 452−458. DOI: 10.1097/RLU.0000000000002578. [16] Pauwels E, Cleeren F, Tshibangu T, et al. [18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients[J]. Eur J Nucl Med Mol Imaging, 2020, 47(13): 3033−3046. DOI: 10.1007/s00259-020-04918-4. [17] 邢宇, 赵新明. 放射性核素标记HER2亲和体分子探针精准诊疗的研究进展[J]. 国际放射医学核医学杂志, 2016, 40(2): 139−144. DOI: 10.3760/cma.j.issn.1673-4114.2016.02.011.
Xing Y, Zhao XM. Advances in radionuclide-labeled HER2 affibody molecular probes for precise diagnosis and treatment[J]. Int J Radiat Med Nucl Med, 2016, 40(2): 139−144. DOI: 10.3760/cma.j.issn.1673-4114.2016.02.011.[18] Zhang JM, Zhao XM, Wang SJ, et al. Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with 99mTc-peptide-ZHER2:342[J]. Nucl Med Biol, 2015, 42(6): 541−546. DOI: 10.1016/j.nucmedbio.2015.02.002. [19] Jiao HL, Zhao XM, Liu JH, et al. In vivo imaging characterization and anticancer efficacy of a novel HER2 affibody and pemetrexed conjugate in lung cancer model[J]. Nucl Med Biol, 2019, 68/69: 31−39. DOI: 10.1016/j.nucmedbio.2018.11.004. [20] Han JY, Zhao Y, Zhao XM, et al. Therapeutic efficacy and imaging assessment of the HER2-targeting chemotherapy drug ZHER2: V2-pemetrexed in lung adenocarcinoma xenografts[J]. Invest New Drugs, 2020, 38(4): 1031−1043. DOI: 10.1007/s10637-019-00876-3. [21] Heskamp S, Laverman P, Rosik D, et al. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer[J]. J Nucl Med, 2012, 53(1): 146−153. DOI: 10.2967/jnumed.111.093047. [22] Glaser M, Iveson P, Hoppmann S, et al. Three methods for 18F labeling of the HER2-binding affibody molecule ZHER2: 2891 including preclinical assessment[J]. J Nucl Med, 2013, 54(11): 1981−1988. DOI: 10.2967/jnumed.113.122465. [23] Xu YP, Bai ZC, Huang QH, et al. PET of HER2 expression with a novel 18FAl labeled affibody[J/OL]. J Cancer, 2017, 8(7): 1170−1178[2020-12-24]. https://www.jcancer.org/v08p1170.htm. DOI: 10.7150/jca.18070. [24] Loktev A, Lindner T, Mier W, et al. A tumor-imaging method targeting cancer-associated fibroblasts[J]. J Nucl Med, 2018, 59(9): 1423−1429. DOI: 10.2967/jnumed.118.210435. [25] Kratochwil C, Flechsig P, Lindner T, et al. 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer[J]. J Nucl Med, 2019, 60(6): 801−805. DOI: 10.2967/jnumed.119.227967. [26] Watabe T, Liu YW, Kaneda-Nakashima K, et al. Theranostics targeting fibroblast activation protein in the tumor stroma: 64Cu- and 225Ac-labeled FAPI-04 in pancreatic cancer xenograft mouse models[J]. J Nucl Med, 2020, 61(4): 563−569. DOI: 10.2967/jnumed.119.233122. [27] Lindner T, Altmann A, Krämer S, et al. Design and development of 99mTc-labeled FAPI tracers for SPECT imaging and 188Re therapy[J]. J Nucl Med, 2020, 61(10): 1507−1513. DOI: 10.2967/jnumed.119.239731. [28] Giesel FL, Adeberg S, Syed M, et al. FAPI-74 PET/CT using either 18F-AlF or cold-kit 68Ga-labeling: biodistribution, radiation dosimetry, and tumor delineation in lung cancer patients[J]. J Nucl Med, 2021, 62(2): 201−207. DOI: 10.2967/jnumed.120.245084. [29] Calais J, Mona CE. Will FAPI PET/CT replace FDG PET/CT in the next decade? point—an important diagnostic, phenotypic and biomarker role[J]. AJR Am J Roentgenol, 2021, 216(2): 305−306. DOI: 10.2214/AJR.20.24302.